MyFinsight
Home
Blog
About
Maturities and sales of
marketable securities
$53,313K
Exercise of common stock
options for cash
$37K
Net cash (used in)
provided by investing...
$45,729K
Net cash provided by
financing activities
$37K
Canceled cashflow
$7,584K
Net increase in
cash, cash...
$1,405K
Canceled cashflow
$44,361K
Purchases of marketable
securities
$7,537K
Purchases of property and
equipment
$47K
Accrued research and
development liabilities
$10,921K
Stock-based compensation
$7,227K
Accrued compensation
and benefits
$2,369K
Accrued professional
services
$509K
Net accretion of
premiums and discounts on...
-$405K
Amortization of right-of-use
assets
$115K
Depreciation of property and
equipment
$76K
Other non cash
adjustments, net
-$7K
Net cash used in
operating activities
-$44,361K
Canceled cashflow
$21,629K
Net loss
-$56,454K
Accounts payble
-$5,330K
Prepaid expense and
other currents assets
$1,925K
Other non-current
assets
$1,557K
Other accrued
liabilities
-$350K
Balances due to and from
related parties
$245K
Operating lease
liabilities
-$129K
Back
Back
Cash Flow
BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc. (BBOT)
source: myfinsight.com